3 Stocks Moving The Health Care Sector Upward

TheStreet highlights 3 stocks pushing the health care sector higher today.
By Chris Dow ,

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 105 points (-0.6%) at 17,872 as of Tuesday, March 31, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,171 issues advancing vs. 1,802 declining with 173 unchanged.

The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.4%. A company within the sector that increased today was

AbbVie

(

ABBV

), up 0.9%. On the negative front, top decliners within the sector include

Alexion Pharmaceuticals

(

ALXN

), down 3.0%,

Novartis

(

NVS

), down 2.4%,

GlaxoSmithKline

(

GSK

), down 2.1%,

Sanofi

(

SNY

), down 2.0% and

Gilead

(

GILD

), down 2.0%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3.

Dr Reddy Laboratories

(

RDY

) is one of the companies pushing the Health Care sector higher today. As of noon trading, Dr Reddy Laboratories is up $2.35 (4.2%) to $58.02 on heavy volume. Thus far, 376,970 shares of Dr Reddy Laboratories exchanged hands as compared to its average daily volume of 318,900 shares. The stock has ranged in price between $55.70-$58.07 after having opened the day at $55.81 as compared to the previous trading day's close of $55.67.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr Reddy Laboratories has a market cap of $9.3 billion and is part of the drugs industry. Shares are up 10.3% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates Dr Reddy Laboratories a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Dr Reddy Laboratories

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Dr Reddy Laboratories Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Teva Pharmaceutical Industries

(

TEVA

) is up $0.66 (1.1%) to $63.18 on average volume. Thus far, 2.4 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.5 million shares. The stock has ranged in price between $62.25-$63.47 after having opened the day at $62.79 as compared to the previous trading day's close of $62.52.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. Teva Pharmaceutical Industries has a market cap of $52.8 billion and is part of the drugs industry. Shares are up 8.7% year-to-date as of the close of trading on Monday. Currently there are 13 analysts who rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates

Teva Pharmaceutical Industries

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Teva Pharmaceutical Industries Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Express Scripts

(

ESRX

) is up $2.46 (2.9%) to $87.87 on heavy volume. Thus far, 3.3 million shares of Express Scripts exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $85.25-$88.19 after having opened the day at $85.38 as compared to the previous trading day's close of $85.40.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations. Express Scripts has a market cap of $60.0 billion and is part of the health services industry. Shares are up 0.9% year-to-date as of the close of trading on Monday. Currently there are 14 analysts who rate Express Scripts a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Express Scripts

as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth, revenue growth, reasonable valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Express Scripts Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

null

Loading ...